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B
arrett's esophagus (BE) is the strongest risk factor for esophageal adenocarcinoma (EAC). [1] [2] [3] Gastrointestinal societies recommend endoscopic surveillance in patients with BE to enable early detection of dysplasia and malignancy. 4, 5 Recently, Gaddam et al 6 have reported that persistence of nondysplastic BE (NBDE) on repeated biopsies predicts lower risk of progression, suggesting that these patients could undergo less intensive surveillance. Conversely, there is also evidence suggesting that the risk of progression in BE continues to increase over time. 7, 8 Therefore, we aimed to investigate if persistence of NBDE in consecutive surveillance biopsies reduces the risk of progression to EAC, providing justification for prolonging surveillance intervals.
Methods
Study subjects were identified from the Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus registry, a prospective multicenter registry of 1998 longsegment BE subjects and 952 EAC patients.
All subjects with a histologic diagnosis of NDBE in the Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus registry were identified. "Progressors" were defined as NDBE subjects who developed high-grade dysplasia (HGD)/EAC 12 months after the first NDBE biopsy (index date). Subjects who progressed to HGD/EAC within 12 months of index diagnosis or had missing data were excluded. Subjects with a histologic diagnosis of NDBE on the index examination and at least 1 additional follow-up endoscopic surveillance examination with biopsies were included in the study.
Subjects were categorized into 5 groups based on the number of consecutive biopsies that showed NDBE. Subjects in Groups 1, 2, 3, 4, and 5 had 1, 2, 3, 4, and 5 consecutive biopsies that showed NDBE, respectively, before the last follow-up biopsy. For subjects who never progressed beyond NDBE, all NDBE biopsies except the last NDBE biopsy were counted toward the number of consecutive biopsies. For subjects who progressed beyond NDBE, all NDBE biopsies until the first biopsy that showed low-grade dysplasia, HGD, or EAC were counted. Time zero (beginning of follow-up) for all groups began at the penultimate endoscopy before the last endoscopy.
Cox proportional hazards models were used to evaluate if the persistence of NDBE in consecutive biopsies reduced the risk of progression to HGD/EAC. The time to progression among the 5 groups was compared using Kaplan-Meier curves.
Results
A total of 634 subjects with NDBE at index date were identified, of which 480 subjects were included after excluding those who did not have follow-up biopsy (140 subjects), progressed within 12 months of index date (5 subjects), or had missing data (9 subjects).
The mean (standard deviation) age of the study population was 63.0 (11.6) years and 78.1% were males. Mean (standard deviation) BE length was 5.7 (2.9) cm. Mean (standard deviation) interval between surveillance biopsies was 1.8 (1.3) years. Sixteen subjects progressed to HGD/EAC over a follow-up period of 1832 patientyears, with an overall annual risk of progression of 0.87%. Of these, 2 progressed to EAC (annual risk, 0.11%; 95% confidence interval, 0.03%-0.44%) and 14 progressed to HGD (annual risk, 0.76%; 95% confidence interval, 0.45%-1.29%). Table 1 summarizes the baseline characteristics and progression risk across the 5 study groups.
On univariate and multivariate analyses adjusting for age, sex, and BE length (Table 1, Figure 1 ) there was no statistical difference in the risk of progression among the 5 study groups (P ¼ .684).
Discussion
In this cohort study from a large multicenter prospective BE registry, we did not find a statistically significant decrease in the risk of progression in subjects with multiple endoscopies showing NDBE.
Gaddam et al 6 reported that persistence of NDBE on consecutive endoscopies was associated with a lower likelihood of progression to EAC and suggested lengthening surveillance intervals and possible discontinuation of surveillance in patients with persistent NDBE. Unlike the current study, the 5 groups in the previous study were not mutually exclusive with Group 1 including subjects in Groups 2, 3, 4, and 5. Similarly, Group 2 included subjects from Groups 3, 4, and 5, and so forth. Otherwise, the 2 studies are fairly comparable in terms of variables adjusted in analysis and the risk of HGD/EAC in the study cohorts (0.52% vs 0.75% per year). Our results are similar to a previous study by Bhat et al, 7 who reported that the risk of progression to EAC does not decrease over time.
The current study's strengths include inclusion of all subjects from a prospective multicenter registry, absence of a misclassification bias given long-segment BE, and interpretation of all histology by specialized gastrointestinal pathologists. The small number of progressors is a potential limitation reducing power to assess associations.
In summary, in this well-defined cohort of NDBE subjects, the persistence of NDBE in consecutive biopsies did not predict lower risk of progression to HGD/EAC. Additional data are required before increasing the interval between surveillance endoscopies based on persistence of NDBE.
